(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
2024-04780-01
2024-10-28
2028-05-15
Klinisk läkemedelsprövning (CTR)
Bayer AG
Godkänd
2024-10-04
Diseases [C] - Neoplasms [C04]
Region Vaesterbotten, Region Skane Skanes Universitetssjukhus
Lulea, Sundsvall, Umea, Lund, Ostersund
2024-511319-91-00
Therapeutic confirmatory (Phase III)
Forskningspersoner
5
Man, Kvinna
65+, 18-64
Historik
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
2024-04780-01
2024-10-28
2028-05-15
Klinisk läkemedelsprövning (CTR)
Bayer AG
Godkänd
2024-10-04
Diseases [C] - Neoplasms [C04]
Region Vaesterbotten, Region Skane Skanes Universitetssjukhus
Umea, Lund
2024-511319-91-00
Therapeutic confirmatory (Phase III)
Forskningspersoner
5
Man, Kvinna
65+, 18-64
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
2025-00655-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
Bayer AG
Godkänd
2025-04-09
(ingen förändring)
Diseases [C] - Neoplasms [C04]
(ingen förändring)
Lulea, Sundsvall, Umea, Lund, Ostersund
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
5
(ingen förändring)
(ingen förändring)
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
2025-00656-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
Bayer AG
Godkänd
2025-04-09
(ingen förändring)
Diseases [C] - Neoplasms [C04]
(ingen förändring)
Lulea, Sundsvall, Umea, Lund, Ostersund
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
5
(ingen förändring)
(ingen förändring)
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
2025-04252-02
(ingen förändring)
(ingen förändring)
(ingen förändring)
Bayer AG
Godkänd
2025-08-25
(ingen förändring)
Diseases [C] - Neoplasms [C04]
(ingen förändring)
(ingen förändring)
(ingen förändring)
Therapeutic confirmatory (Phase III)
Forskningspersoner
5
(ingen förändring)
(ingen förändring)